Adverse outcomes in participants with elevated OPG levels were only observed for CHD and COPD-related mortality in participants with an eGFR of <60 ml/min/1.73m2 in multivariable-adjusted models (Table 3). This evidence concerns the gene TNFRSF11B and coronary artery disorder.